Could OX40 agonist antibody promote activation of the anti‐tumor immune response in gastric cancer?

Abstract

OX40 as a therapeutic agent has been investigated in many preclinical tumor models. Our findings suggest that of levels of costimulatory in T cells in GC will direct future studies on the role that costimulatory receptors play in the failure of T cell-mediated immunity.